VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021

Feb 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-24

Reporting Person: Arbuckle Stuart A (EVP, Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-24	Common Stock	F	2898	$217.57	Disposed	44737	Direct
2021-02-25	Common Stock	S	380	$211.39	Disposed	44357	Direct
2021-02-25	Common Stock	S	900	$212.52	Disposed	43457	Direct
2021-02-25	Common Stock	S	1400	$213.55	Disposed	42057	Direct
2021-02-25	Common Stock	S	400	$214.32	Disposed	41657	Direct
2021-02-25	Common Stock	S	300	$215.62	Disposed	41357	Direct
2021-02-25	Common Stock	S	254	$216.57	Disposed	41103	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	140	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $211.39 (range $210.76 to $211.68).

F3: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $212.52 (range $212.05 to $213.02).

F5: Open market sales reported on this line occurred at a weighted average price of $213.55 (range $213.09 to $214.08).

F6: Open market sales reported on this line occurred at a weighted average price of $214.32 (range $214.10 to $214.62).

F7: Open market sales reported on this line occurred at a weighted average price of $215.62 (range $215.37 to $215.84).

F8: Open market sales reported on this line occurred at a weighted average price of $216.57 (range $216.50 to $216.62).